Current literature describes symptom improvement in roughly 60–75% of trial participants, though definitions of 'improvement' vary widely and placebo response rates in menopausal symptom trials historically exceed 40%. No head-to-head trials against hormone therapy exist. Real-world outcomes beyond trial settings remain unreported. The wide range reflects heterogeneous populations and measurement methods rather than robust efficacy.
Approximately 10 registered trials are investigating stem cell and exosome therapies for menopause-related symptoms. A 2023 small-scale study of placental MSCs reported subjective improvement in hot flush frequency in 70% of participants over 12 weeks, though follow-up assessments remain limited. Exosome trials have focused on anti-inflammatory signalling rather than direct hormone replacement. No large multicentre randomised controlled trials have yet demonstrated safety or efficacy comparable to hormone therapy, and recruitment for new menopause-focused stem cell studies has stalled. Evidence remains preliminary and largely mechanistic.
Am I a candidate? → · Menopause & Hormonal Health: full overview → · Menopause & Hormonal Health cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估